Bermes Project

La exposición al #amianto es el principal factor de riesgo para el #mesothelioma. El objetivo principal @bermesproject es el desarrollo una nueva molécula con un mecanismo de acción disruptivo y que ha mostrado actividad farmacológica en este tumor difícil de tratar. #asbestos

CRL2FEM1B uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer dlvr.it/TShprL

New online! Direct roles of long non-coding RNAs in transcription activation dlvr.it/TSK9MJ

Review @cancer_cell @UofOklahoma Cancer cachexia: A tumor-driven disorder of whole-body homeostasis cell.com/cancer-cell/fu…

Opening Plenary to feature spectacular science from pioneering cancer researchers aacrmeetingnews.org/opening-plenar…

In the latest issue! Hallmarks of cancer—Then and now, and beyond dlvr.it/TS4Plc

A new article summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment. Read the Clinical Practice article “Celiac Disease” by Joseph A. Murray, MD, and Steffen Husby, MD, DMSc, from @mayoclinic and the University of Southern Denmark: nejm.org/doi/full/10.10…

Dendritic cells are innate immune cells that regulate the quality, magnitude, and duration of antitumor responses. Conventional type 1 dendritic cells (cDC1s) are crucial in this capacity but are paradoxically rare and functionally impaired in most solid tumors. This is a major barrier to effective immunotherapy. The molecular underpinnings of cDC1 dysfunction within the tumor microenvironment are poorly understood. In a new Science study, researchers report that mitochondrial fitness is important for cDC1 function. They also demonstrate the therapeutic rescue of cDC1 function within the tumor microenvironment in mice, which provides a framework for metabolically reprogramming dendritic cells to restore antitumor immunity. Learn more in a new #SciencePerspective: scim.ag/4c3CX1b

We should be prioritizing prevention of cancer instead of the major focus on detection and treatment. A new @CellCellPress perspective cell.com/cell/fulltext/…

El Gobierno reforzará la seguridad de los trabajadores frente al #amianto tras la amonestación de Bruselas elpais.com/economia/2026-… vía @el_pais

Alnylam & RNAi Therapeutics: Silencing Disease. Amplifying Life. youtu.be/Cxj8ohdnJ54?is… vía @YouTube

AI for cancer treatment information: Can academia stay in the game? dlvr.it/TRWgWH

Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges rdcu.be/e8qhG nature.com/articles/s4157… This Review in the March issue discusses generating and maintaining organoids, and their applications in disease modelling and drug screening

Discovery of why only some early tumors survive could help catch and treat cancer at very earliest stages , via @EurekAlert! @Cambridge_Uni eurekalert.org/news-releases/…

New preprint released 🪇 Which tRNAs are used by ribosomes during translation? We introduce tRIBO-seq, a nanopore method to sequence ribosome-associated tRNAs and track how the active tRNA pool changes across stress conditions. biorxiv.org/content/10.648… A thread 🧵

Claudins - The Next Big Solid Tumor Target? A major 2026 review in Nature Reviews Cancer dissects why CLDN proteins are rapidly emerging as precision oncology targets Here’s what every oncologist should know: 🧬 What are Claudins? Tight junction transmembrane proteins maintaining epithelial polarity. Frequently dysregulated and overexpressed across solid tumors. 🔥 Why they matter in cancer •Promote proliferation •Drive EMT & stemness •Modulate fibrosis •Shape immune microenvironment •Contribute to therapeutic resistance 🎯 Therapeutic breakthrough CLDN18.2 targeting has achieved regulatory approval - validating claudins as druggable surface antigens 🚀 Therapeutic platforms in development •Monoclonal antibodies •ADCs •Bispecific antibodies •CAR-T cells •Intracellular pathway targeting 🧠 Precision angle Surface overexpression + subtype correlation + biomarker-enriched selection = scalable solid tumor strategy. Claudins may follow the HER2 playbook. From barrier proteins to immunotherapy targets. 📖 Full review: Nature Reviews Cancer 2026 #OncoTwitter #MedTwitter #PrecisionOncology #Immunotherapy #TargetedTherapy #GastricCancer #GIOncology #SolidTumors #ADC #CART @NatureRevCancer @ASCO @myESMO @OncoAlert @ESMO_Open

🧬🤖 Evo 2, una nueva IA entrenada con 128 000 especies, ya es capaz de leer y escribir genomas y predecir mutaciones con más del 90 % de precisión. Un salto clave en la biología generativa, publicado en @Nature Por @bajoelbillete agenciasinc.es/Noticias/Una-I…

DREAM3R Phase 3 results: durvalumab + chemo showed signals for mesothelioma but fell short of statistical proof. The trial didn't fail. The math was more complicated than expected.

Telefónica exhibe su apuesta cuántica en MWC con un superordenador de 54 qubits para investigar contra el cáncer | Por @MartaGasc desde MWC 20minutos.es/tecnologia/act…

La clave para atacar proteínas 'inabordables': investigadores del @IRBBarcelona revelan el mecanismo de un fármaco pionero biotech-spain.com/es/articles/la…

Organoid analytical toolkits bit.ly/44VNRUg